Vitamin D as a Modifier of Serum Hepcidin in Children With Chronic Kidney Disease
Status:
Completed
Trial end date:
2015-04-01
Target enrollment:
Participant gender:
Summary
This research is being done to study the effectiveness of vitamin D (cholecalciferol) to
modify hepcidin levels in children with chronic kidney disease (CKD). Anemia is a common
problem in children with CKD. Anemia is when the body does not have enough healthy red blood
cells. Hepcidin is a protein in the blood which interferes with the body's production of red
blood cells. This study will see if vitamin D lowers hepcidin levels in children and young
adults with CKD. If so, it could be used as an additional treatment for anemia in these
children, in addition to the current therapies already in use including iron supplements and
erythropoietin. People between the ages of 1 and 21 with CKD may be considered for this
study.
Phase:
Phase 2
Details
Lead Sponsor:
Johns Hopkins University
Collaborator:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Treatments:
Cholecalciferol Ergocalciferols Hepcidins Vitamin D Vitamins